$IFRX News

InflaRx Announces Participation in September Investor Conferences

Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6

InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx Mulls Feasibility For AAV In Europe

What Do Analysts Say About InflaRx N.V. (IFRX)?

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases - Slideshow

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx N.V. (IFRX) Regains Compliance With Nasdaq

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases